Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
HONG KONG,Nov. 28,2024-- Akeso,Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed,globally pioneering bispecific antibody dru








